Clinical Trial Update: Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS

View source ↗

Summary

A clinical trial comparing Rebif (interferon beta-1a) with Tecfidera (dimethyl fumarate) for six-month outcomes in relapsing-remitting multiple sclerosis has be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)
• Tecfidera (dimethyl fumarate)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Multiple Sclerosis | Status: WITHDRAWN